Received: from DBAPR02MB6102.eurprd02.prod.outlook.com (2603:10a6:10:187::21) by AM0PR02MB5011.eurprd02.prod.outlook.com with HTTPS; Wed, 27 May 2026 07:45:55 +0000 Received: from DB8PR02MB5578.eurprd02.prod.outlook.com ([fe80::504a:bb7e:aef0:82c4]) by DB8PR02MB5578.eurprd02.prod.outlook.com ([fe80::504a:bb7e:aef0:82c4%4]) with mapi id 15.21.0071.011; Wed, 27 May 2026 07:45:53 +0000 Received: from DB8PR02MB5578.eurprd02.prod.outlook.com (2603:10a6:10:38::25) by DBAPR02MB6102.eurprd02.prod.outlook.com (2603:10a6:10:187::21) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.21.71.11; Wed, 27 May 2026 07:45:53 +0000 From: "Carmen Katariina Sikk - RA" To: =?iso-8859-1?Q?K=E4rolin_Jenas_-_RA?= References: In-Reply-To: Subject: =?iso-8859-1?Q?Ed:_=DCks_kiri=2C_kaks_teemat?= Date: Wed, 27 May 2026 10:45:53 +0300 Message-ID: MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="----=_NextPart_000_034F_01DCEE7D.55B06AE0" X-Mailer: Microsoft Outlook 16.0 Authentication-Results: dkim=none (message not signed) header.d=none;dmarc=none action=none header.from=ravimiamet.ee; X-MS-Exchange-Organization-ExpirationStartTime: 27 May 2026 07:45:53.9133 (UTC) X-MS-Exchange-Organization-ExpirationStartTimeReason: OriginalSubmit X-MS-Exchange-Organization-ExpirationInterval: 1:00:00:00.0000000 X-MS-Exchange-Organization-ExpirationIntervalReason: OriginalSubmit X-MS-Exchange-Organization-Network-Message-Id: f8ef4e5f-5cf5-491f-6f8e-08debbc3fb12 X-MS-Exchange-Organization-MessageDirectionality: Originating X-MS-PublicTrafficType: Email X-MS-TrafficTypeDiagnostic: DB8PR02MB5578:EE_|DBAPR02MB6102:EE_|AM0PR02MB5011:EE_ X-MS-Exchange-Organization-AuthSource: DB8PR02MB5578.eurprd02.prod.outlook.com X-MS-Exchange-Organization-AuthAs: Internal X-MS-Office365-Filtering-Correlation-Id: f8ef4e5f-5cf5-491f-6f8e-08debbc3fb12 X-MS-Exchange-AtpMessageProperties: SA X-MS-Exchange-Organization-SCL: 1 X-Microsoft-Antispam: BCL:0;ARA:13230040|31052699007|39142699007|366016|11063799006|56012099006|18002099003|22082099003|55112099003|8096899003|13003099007|41050700001; X-Forefront-Antispam-Report: CIP:255.255.255.255;CTRY:;LANG:et;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:DB8PR02MB5578.eurprd02.prod.outlook.com;PTR:;CAT:NONE;SFS:(13230040)(31052699007)(39142699007)(366016)(11063799006)(56012099006)(18002099003)(22082099003)(55112099003)(8096899003)(13003099007)(41050700001);DIR:INT; X-MS-Exchange-CrossTenant-OriginalArrivalTime: 27 May 2026 07:45:53.8063 (UTC) X-MS-Exchange-CrossTenant-Network-Message-Id: f8ef4e5f-5cf5-491f-6f8e-08debbc3fb12 X-MS-Exchange-CrossTenant-Id: 8fe098d2-428d-4bd4-9803-7195fe96f0e2 X-MS-Exchange-CrossTenant-AuthSource: DB8PR02MB5578.eurprd02.prod.outlook.com X-MS-Exchange-CrossTenant-AuthAs: Internal X-MS-Exchange-CrossTenant-FromEntityHeader: Hosted X-MS-Exchange-Transport-CrossTenantHeadersStamped: DBAPR02MB6102 X-MS-Exchange-Transport-EndToEndLatency: 00:00:01.5713774 X-MS-Exchange-Processed-By-BccFoldering: 15.21.0071.000 X-Microsoft-Antispam-Mailbox-Delivery: ucf:0;jmr:0;auth:0;dest:I;ENG:(910005)(944506478)(944626604)(920097)(425001)(930201)(20251009189)(140003); X-Microsoft-Antispam-Message-Info: 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 Thread-Index: AQI2hQhGdqBZ62IZ3s5M+7bd9lBfAwHDgcj1 X-MS-Has-Attach: X-MS-TNEF-Correlator: X-CodeTwoProcessed: true X-MS-Exchange-Organization-AuthMechanism: 04 X-MS-Exchange-ExternalInOutlookResult: NotEnabled Content-Language: et x-ms-exchange-organization-originalclientipaddress: 45.156.32.33 x-ms-exchange-organization-originalserveripaddress: 2603:10a6:10:38::25 acceptlanguage: en-US msip_labels: MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Enabled=True;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SiteId=8fe098d2-428d-4bd4-9803-7195fe96f0e2;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SetDate=2026-05-27T07:45:53.322Z;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Name=All Employees (unrestricted);MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_ContentBits=1;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Method=Standard; X-OlkEid: 000000004C30E2D3CD34B4428531CBEB8A7CAB89070034AD76187591974DBF6C4F76951C873A0100020000000000B04CDEF8D3227A448511457FBBCE9C870000000009B6000046564D7E20DA904A98D6395AE82E1C23 X-MS-Exchange-Organization-ModifySensitivityLabel: 00000000-0000-0000-0000-000000000000;defa4170-0d19-0005-0004-bc88714345d2 x-codetwo-clientsignature-inserted: true X-MS-Exchange-CrossTenant-MailboxType: HOSTED X-MS-Exchange-CrossTenant-UserPrincipalName: I1FFKjGoeJWL4M04a79rhldPRTYhNF9N7CSgTQ55Tz7JT4hcJLxrAYVsfZxZKCYnKX418ZvbovDPNcKj66ZbtSJDB/Xmb6jV9a1jHm4wWm0= This is a multipart message in MIME format. ------=_NextPart_000_034F_01DCEE7D.55B06AE0 Content-Type: text/plain; charset="iso-8859-1" Content-Transfer-Encoding: 8bit Selles e-kirjas sisalduv teave (kaasa arvatud manused) on mõeldud ametialaseks kasutamiseks ning seda võivad kasutada vaid e-kirja adressaadid. E-kirjas sisalduvat teavet ei tohi ilma saatja selgelt väljendatud loata edasi saata ega mis tahes viisil kolmandatele isikutele avaldada. Juhul, kui Te olete saanud käesoleva e-kirja eksituse tõttu, teavitage sellest koheselt saatjat ning kustutage e-kiri. This e-mail and any attachments transmitted may contain confidential and privileged information. If you are not the intended recipient, please notify the sender immediately by returning the e-mail and permanently deleting what you have received. Any dissemination or use of this information by a third person without permission is prohibited and may be illegal. _____ Saatja: Hanneli Rudi > Saadetud: teisipäev, 26. mai 2026 11:51 Adressaat: Carmen Katariina Sikk - RA > Teema: Üks kiri, kaks teemat Tähelepanu! Tegemist on välisvõrgust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. Tere Oma kodulehel annate teada, et mitmes riigis on peatatud Medtrumi glükoosiseire seadmete müük, sest esineb mõõteviga. Kui levinud on need seadmed Eestis ja miks Eestis nende müük jätkuda võib, kuigi on oht eksida insuliinikoguse määramisel? Teine teema puudutab semaglutiidide kasutamist. Kas oleks võimalik teada saada, kui palju ja mis diagnooside alusel saab tervisekassa soodustusega Ozempicut jt analoogseid ravimeid, kui palju müüakse neid ilma soodustuseta? Milliseid muudatusi ravimiamet seoses kaalulangutusravimitega plaanib ja millal need otsused langetatakse? Mõlemad teemad on nö taustaküsimused ja kedagi kaamera ette kohe ei palu. Hanneli Rudi AK toimetaja 55 35 816 ------=_NextPart_000_034F_01DCEE7D.55B06AE0 Content-Type: text/html; charset="iso-8859-1" Content-Transfer-Encoding: quoted-printable

 

 

Selles e-kirjas = sisalduv teave (kaasa arvatud manused) on m=F5eldud ametialaseks = kasutamiseks ning seda v=F5ivad kasutada vaid e-kirja adressaadid. = E-kirjas sisalduvat teavet ei tohi ilma saatja selgelt v=E4ljendatud = loata edasi saata ega mis tahes viisil kolmandatele isikutele avaldada. = Juhul, kui Te olete saanud k=E4esoleva e-kirja eksituse t=F5ttu, = teavitage sellest koheselt saatjat ning kustutage e-kiri. 
This = e-mail and any attachments transmitted may contain confidential and = privileged information. If you are not the intended recipient, please = notify the sender immediately by returning the e-mail and = permanently deleting what you have received. Any dissemination or = use of this information by a third person without permission is = prohibited and may be illegal. 

Saatja: Hanneli Rudi <hanneli.rudi@err.ee>
Saa= detud: teisip=E4ev, 26. mai 2026 11:51
Adressaat: Carmen = Katariina Sikk - RA <carmenkatariina.sikk@r= avimiamet.ee>
Teema: =DCks kiri, kaks = teemat =

 

T=E4helepanu! Tegemist on v=E4lisv=F5rgust saabunud = kirjaga.
Tundmatu saatja korral palume linke ja faile mitte = avada.

Tere

 

Oma kodulehel annate teada, et mitmes riigis on = peatatud Medtrumi gl=FCkoosiseire seadmete m=FC=FCk, sest esineb = m=F5=F5teviga. Kui levinud on need seadmed Eestis ja miks Eestis nende = m=FC=FCk j=E4tkuda v=F5ib, kuigi on oht eksida insuliinikoguse = m=E4=E4ramisel?

 

Teine teema puudutab semaglutiidide kasutamist. Kas = oleks v=F5imalik teada saada, kui palju ja mis diagnooside alusel saab = tervisekassa soodustusega Ozempicut jt analoogseid ravimeid, kui palju = m=FC=FCakse neid ilma soodustuseta? Milliseid muudatusi ravimiamet = seoses kaalulangutusravimitega plaanib ja millal need otsused = langetatakse?

 

M=F5lemad teemad on n=F6 taustak=FCsimused ja kedagi = kaamera ette kohe ei palu.

Hanneli Rudi

AK toimetaja

55 35 = 816

------=_NextPart_000_034F_01DCEE7D.55B06AE0--